BR112022024754A2 - Composições e métodos para tratar covid longo - Google Patents

Composições e métodos para tratar covid longo

Info

Publication number
BR112022024754A2
BR112022024754A2 BR112022024754A BR112022024754A BR112022024754A2 BR 112022024754 A2 BR112022024754 A2 BR 112022024754A2 BR 112022024754 A BR112022024754 A BR 112022024754A BR 112022024754 A BR112022024754 A BR 112022024754A BR 112022024754 A2 BR112022024754 A2 BR 112022024754A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
covid
treat long
long covid
Prior art date
Application number
BR112022024754A
Other languages
English (en)
Inventor
K Equels Thomas
R Strayer David
L Young Diane
Original Assignee
Aim Immunotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aim Immunotech Inc filed Critical Aim Immunotech Inc
Publication of BR112022024754A2 publication Critical patent/BR112022024754A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA TRATAR COVID LONGO. A presente invenção refere-se a composições e métodos para tratar um indivíduo previamente infectado com um vírus e afligido com sintomas de fadiga pós-viral, como, por exemplo, Covid Longo. As composições e métodos compreendem uma quantidade terapeuticamente eficaz de uma composição compreendendo tdsRNA de RNA de fita dupla terapêutico.
BR112022024754A 2020-06-05 2021-06-07 Composições e métodos para tratar covid longo BR112022024754A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063035681P 2020-06-05 2020-06-05
US202063125195P 2020-12-14 2020-12-14
PCT/US2021/036235 WO2021248134A1 (en) 2020-06-05 2021-06-07 Compositions and methods for treating long covid

Publications (1)

Publication Number Publication Date
BR112022024754A2 true BR112022024754A2 (pt) 2023-03-07

Family

ID=78829958

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022024754A BR112022024754A2 (pt) 2020-06-05 2021-06-07 Composições e métodos para tratar covid longo

Country Status (9)

Country Link
US (1) US20220280547A1 (pt)
EP (1) EP4096675A4 (pt)
JP (1) JP2023529851A (pt)
AU (1) AU2021282735A1 (pt)
BR (1) BR112022024754A2 (pt)
CA (1) CA3181502A1 (pt)
MX (1) MX2022015365A (pt)
WO (1) WO2021248134A1 (pt)
ZA (1) ZA202209180B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2032813A (en) * 2021-08-20 2023-02-27 Aim Immunotech Inc Compositions and methods for treating post-covid conditions of fatigue
WO2023049904A1 (en) * 2021-09-24 2023-03-30 Aim Immunotech Inc. Compositions and methods for enhancing and expanding infection induced immunity
WO2023146812A1 (en) * 2022-01-28 2023-08-03 Incelldx, Inc. Methods of treating a subject for long-haul covid-19, and compositions for use in the same
WO2024118480A1 (en) * 2022-11-28 2024-06-06 Epiphany Biosciences Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6130206A (en) * 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
WO2005009337A2 (en) * 2003-05-16 2005-02-03 Hemispherx Biopharma Treating severe acute respiratory syndrome
JP5689413B2 (ja) * 2008-05-21 2015-03-25 ライニッシュ フリードリッヒ−ウィルヘルムズ−ユニバーシタット ボン 平滑末端を有する５’三リン酸オリゴヌクレオチドおよびその使用
US20110196020A1 (en) * 2008-10-10 2011-08-11 Carter William A Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3)

Also Published As

Publication number Publication date
US20220280547A1 (en) 2022-09-08
WO2021248134A1 (en) 2021-12-09
EP4096675A4 (en) 2023-12-06
CA3181502A1 (en) 2021-12-09
AU2021282735A1 (en) 2023-02-02
JP2023529851A (ja) 2023-07-12
ZA202209180B (en) 2023-12-20
EP4096675A1 (en) 2022-12-07
MX2022015365A (es) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112022024754A2 (pt) Composições e métodos para tratar covid longo
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112022007677A2 (pt) L-asparaginase recombinante
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112017012327A2 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112018000542A2 (pt) composições de irna de transtirretina (ttr) e métodos de uso das mesmas para o tratamento ou prevenção de doenças associadas à ttr
BR112019005548A2 (pt) tratamento da doença de huntington com aav
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112019010342A2 (pt) composições do irna de serpina1 e métodos de uso destas
CO2018002557A2 (es) Ácido nucléico antisentido para tratar la distrofia muscular de duchenne
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
MX2021006745A (es) Constructos de iarn modificados quimicamente y usos de estos.
BR112019003731A2 (pt) aplicação de pridopidina para tratamento de distonias
BR112019001039A2 (pt) composição para uso no tratamento de transtorno depressivo maior
BR112018071477A2 (pt) oligômeros antisenso e métodos de utilização dos mesmos para tratamento de doenças associadas com o gene da alfa-glicosidase ácida
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
BR112012027080A2 (pt) composições orgânicas para tratar doenças relacionadas a beta - ena
CL2018001548A1 (es) Tratamiento de colestasis intrahepática y enfermedades del hígado relacionadas
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
BR112017023448A2 (pt) composições anti-fitopatogênicas
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
CU24699B1 (es) Composiciones para tratar y/o prevenir la infección por el virus de la hepatitis b